Immuno-oncology in GI tumours
Standard
Immuno-oncology in GI tumours : Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. / Stein, Alexander; Markus, Moehler; Jörg, Trojan; Eray, Goekkurt; Vogel, Arndt.
In: CRIT REV ONCOL HEMAT, Vol. 130, 10.2018, p. 13-26.Research output: SCORING: Contribution to journal › SCORING: Review article › Transfer
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Immuno-oncology in GI tumours
T2 - Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
AU - Stein, Alexander
AU - Markus, Moehler
AU - Jörg, Trojan
AU - Eray, Goekkurt
AU - Vogel, Arndt
N1 - Copyright © 2018 Elsevier B.V. All rights reserved.
PY - 2018/10
Y1 - 2018/10
N2 - The use of immune checkpoint inhibitors constitutes an emerging therapeutic field for the therapy of gastrointestinal (GI) malignancies following the recent FDA approvals of PD-1 inhibitors for esophago-gastric adenocarcinoma, hepatocellular carcinoma and for microsatellite-instable tumors, which are mainly colorectal cancers. This paper reviews the clinical evidence end of 2017 and discusses the clinical development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in GI-tract cancers. Since 2014, these antagonists of the PD-1/PD-L1 axis have gained approval for use in numerous other tumors. Phase II trials and phase I expansion cohorts demonstrate clinical activity in patients with oesophageal, gastric, colorectal, anal and hepatic cancer. Signals of outstanding efficacy are particularly observed in biomarker selected populations and for certain combination regimen. Comprehensive phase III development programs have been initiated in oesophageal and gastric cancer, with randomized trials ongoing in hepatocellular and colorectal cancer as well.
AB - The use of immune checkpoint inhibitors constitutes an emerging therapeutic field for the therapy of gastrointestinal (GI) malignancies following the recent FDA approvals of PD-1 inhibitors for esophago-gastric adenocarcinoma, hepatocellular carcinoma and for microsatellite-instable tumors, which are mainly colorectal cancers. This paper reviews the clinical evidence end of 2017 and discusses the clinical development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in GI-tract cancers. Since 2014, these antagonists of the PD-1/PD-L1 axis have gained approval for use in numerous other tumors. Phase II trials and phase I expansion cohorts demonstrate clinical activity in patients with oesophageal, gastric, colorectal, anal and hepatic cancer. Signals of outstanding efficacy are particularly observed in biomarker selected populations and for certain combination regimen. Comprehensive phase III development programs have been initiated in oesophageal and gastric cancer, with randomized trials ongoing in hepatocellular and colorectal cancer as well.
KW - Journal Article
KW - Review
U2 - 10.1016/j.critrevonc.2018.07.001
DO - 10.1016/j.critrevonc.2018.07.001
M3 - SCORING: Review article
C2 - 30196908
VL - 130
SP - 13
EP - 26
JO - CRIT REV ONCOL HEMAT
JF - CRIT REV ONCOL HEMAT
SN - 1040-8428
ER -